Assertio Interest Expense from 2010 to 2026

Stocks . USA . 
Stock . Assertio Therapeutics
ASRT Stock  USD 11.50  -0.13  -1.12%   
Assertio Therapeutics' shows a recovering structural trend supported by multi-year data. Financial forecasts anticipate softening toward approximately 3.3 M. Interest Expense is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. View All Fundamentals
 
Interest Expense  
 First Reported
2000-03-31
 Previous Quarter
768 K
 Current Value
770 K
 Quarterly Volatility
7.1 M
Macro event markers
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Financial statement trends for Assertio Therapeutics provide structured context on operating performance and capital structure. This context pairs drivers like Interest Expense of 3.3 M, Total Revenue of 128.4 M or Gross Profit of 112.1 M and ratios such as Price To Sales Ratio of 0.73, Dividend Yield of 0.0 or PTB Ratio of 0.59 with Assertio Therapeutics Valuation and Volatility views.
  
Build AI portfolio with Assertio Stock
Assertio Therapeutics Correlation provides competitor comparison context for Assertio Therapeutics. The view supports competitor context.
Our How to Buy Assertio Stock guide explains the steps to invest in Assertio Therapeutics stock.
The evolution of Interest Expense for Assertio Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Assertio Therapeutics compares to historical norms and industry peers.

Latest Assertio Therapeutics' Interest Expense Growth Pattern

Below is the plot of the Interest Expense of Assertio Therapeutics over the last few years. It is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. Assertio Therapeutics' Interest Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Assertio Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Interest Expense10 Years Trend
Pretty Stable
Compare to OthersAll Fundamentals
   Interest Expense   
       Timeline  

Assertio Interest Expense Regression Statistics

Arithmetic Mean 25,569,762
Geometric Mean0.00
Coefficient Of Variation 123.29
Mean Deviation 27,059,316
Median 7,961,000
Standard Deviation 31,524,138
Sample Variance993.8T
Range83.7M
R-Value-0.14
Mean Square Error1040.4T
R-Squared 0.02
Significance 0.60
Slope-848,623
Total Sum of Squares15900.3T

Assertio Interest Expense History

20263.3 M
20253.5 M
20243 M
20233.4 M
20228 M
202110.2 M
202015.9 M

About Assertio Therapeutics Inc

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois. Assertio Holdings operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. As a micro-cap equity, Assertio Therapeutics is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/E of 4.93, P/B of 0.7, profit margin of -21.06%. Assertio Therapeutics has a market cap of 73.79 M, P/E of 4.93, ROE of -24.48%.

Methodology

Unless otherwise specified, financial data for Assertio Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Assertio (USA Stocks:ASRT) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Assertio Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR. Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Assertio Therapeutics is covered by 4 analysts. 2 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, among others. Updates may occur throughout the day.

Assertio Stock is Curated By:

Gabriel ShpitalnikGabriel Shpitalnik ยท Member of Macroaxis Editorial Board

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Assertio Stock Analysis

Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY